ONESOURCE
OneSource Specialty Pharma Limited
Each stock's 10,000-path forecast, rendered as light.
OneSource Specialty Pharma Limited (ONESOURCE) Stock Analysis & Case Study
Is ONESOURCE a good buy? The data-driven verdict.
OneSource Specialty Pharma Limited (ONESOURCE) trades at ₹1,576,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, OneSource Specialty Pharma Limited (ONESOURCE) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 509.0× earnings, ROE of -1.1%, a 50% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
ONESOURCE fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How ONESOURCE ranks against the 2,373 companies in our screener
- ONESOURCE's market cap of 18,072 Cr ranks in the 84th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ONESOURCE's book value of ₹509 ranks in the 90th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ONESOURCE's promoter holding of 30.5% ranks in the 8th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ONESOURCE's 3-year profit (PAT) growth of 24.0% ranks in the 62nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ONESOURCE's 3-year revenue growth of 232.0% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ONESOURCE's debt-to-equity ratio of 0.26x is lower than 56% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is ONESOURCE overvalued? ONESOURCE P/E vs peers
ONESOURCE trades at 509.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
ONESOURCE share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 1.5y of ONESOURCE history (-5%/yr drift, 46%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| ONESOURCE 2027 | ₹881 | ₹1,582 | ₹2,840 | +0% |
| ONESOURCE 2028 | ₹697 | ₹1,588 | ₹3,619 | +1% |
| ONESOURCE 2029 | ₹590 | ₹1,595 | ₹4,308 | +1% |
| ONESOURCE 2030 | ₹506 | ₹1,601 | ₹5,067 | +2% |
| ONESOURCE 2031 | ₹436 | ₹1,607 | ₹5,927 | +2% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability ONESOURCE goes up, or doubles?
The bull case for ONESOURCE
- OneSource Specialty Pharma Limited is part of the nifty200 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹4,308.
The bear case & risks
- ONESOURCE's P/E of 509.0x is lower than 2% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- High historical volatility (46%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹590.
ONESOURCE volatility & expected range, how bumpy is the ride?
Over the last 1.5 years ONESOURCE compounded at -5%/year with annualized volatility of 46%. That volatility implies a 1-year 80% range of ₹881-₹2,840, the honest backbone behind any single price target.
ONESOURCE price forecast, the full 60-month probability fan
ONESOURCE price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds ONESOURCE hits common targets within the simulated horizon?
Full multi-horizon detail on the ONESOURCE price target & forecast page.
ONESOURCE Piotroski F-Score: 4/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. ONESOURCE scores 4/8, mixed financial health.
ONESOURCE MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy ONESOURCE with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 34.19% | 2.9× |
| Zerodha | 34.16% | 2.9× |
| Groww | 34.29% | 2.9× |
| Dhan | 35.00% | 2.9× |
| Kotak NeoCHEAPEST | 34.13% | 2.9× |
| Paytm Money | 36.88% | 2.7× |
| Pocketful | 34.39% | 2.9× |
| Fyers | 34.48% | 2.9× |
| Anand Rathi | 34.16% | 2.9× |
| Bajaj Broking | 40.00% | 2.5× |
| Share India | 34.29% | 2.9× |
Compare every broker on the ONESOURCE MTF page.
About OneSource Specialty Pharma Limited: sector, index & market-cap context
OneSource Specialty Pharma Limited (ONESOURCE) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹18,072 Cr. See more stocks on our screener.
How the ONESOURCE Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of OneSource Specialty Pharma Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ONESOURCE analysis, FAQs
Is OneSource Specialty Pharma Limited (ONESOURCE) a good buy?
On the numbers, OneSource Specialty Pharma Limited (ONESOURCE) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 509.0× earnings, ROE of -1.1%, a 50% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is ONESOURCE overvalued or undervalued?
ONESOURCE trades at 509.0× earnings, expensive versus the ~22× long-run Nifty average.
What is the ONESOURCE share price target for 2031?
ONESOURCE's probability-weighted 2031 median target is ₹1,607, with an 80% range of ₹436-₹5,927 (10,000-path Monte-Carlo).
What is the probability ONESOURCE doubles in 5 years?
The modelled probability of ONESOURCE reaching ₹3,152 (2×) within 5 years is 25%.
What is the bull case for ONESOURCE?
OneSource Specialty Pharma Limited is part of the nifty200 universe with live, tracked fundamentals on Downstox.
What are the risks in ONESOURCE?
ONESOURCE's P/E of 509.0x is lower than 2% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. High historical volatility (46%/yr) means a wide, bumpy range of outcomes, size positions accordingly.